Strategic Partnerships IBT Bioservices is a versatile CRO offering both in vitro and in vivo capabilities with a broad catalog of reagents and custom development. Target biotechs and pharma companies seeking a one-stop shop CRO and concierge-style support present a compelling cross-sell: expand into their clinical and preclinical programs by offering integrated assay development, custom disease models, and reagent supply.

Expansion Potential Recent partnership press with Dyadic indicates active channel development and distribution partnerships. Leverage this momentum to position IBT as a preferred outsourced R&D partner for partner networks and for CROs looking to broaden their infectious disease and virology model capabilities.

Disease Model Portfolio IBT lists 15+ in vivo efficacy models for viral and bacterial infections and immunogenicity studies. This breadth supports upsell into larger Phase I/II programs and anti-infective portfolios, offering clients accelerated timelines through ready-to-run models and custom development.

Integrated Reagent Store With an online storefront offering recombinant proteins, antibodies, virus-like particles, pseudoviruses, ELISA kits, and reporter cell lines, IBT can monetize repurposed or expanded reagent bundles to customers pursuing rapid assay development and high-throughput screening.

Financial Health Reported revenue range of 25 to 50 million positions IBT as a mid-market CRO with room to scale; growth opportunities exist by expanding into higher-margin, integrated service packages (assay development plus in vivo models) for mid-to-large biotech and pharma clients that require end-to-end support.